NASDAQ:NARI Inari Medical (NARI) Stock Forecast, Price & News $60.33 -1.15 (-1.87%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$60.00▼$62.3850-Day Range$58.97▼$71.1752-Week Range$52.59▼$86.94Volume740,497 shsAverage Volume828,410 shsMarket Capitalization$3.45 billionP/E RatioN/ADividend YieldN/APrice Target$89.11 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Inari Medical MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside47.7% Upside$89.11 Price TargetShort InterestBearish7.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 3 Articles This WeekInsider TradingSelling Shares$11.75 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.27) to $0.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector523rd out of 981 stocksSurgical & Medical Instruments Industry51st out of 97 stocks 3.4 Analyst's Opinion Consensus RatingInari Medical has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $89.11, Inari Medical has a forecasted upside of 47.7% from its current price of $60.33.Amount of Analyst CoverageInari Medical has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.03% of the float of Inari Medical has been sold short.Short Interest Ratio / Days to CoverInari Medical has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Inari Medical has recently increased by 25.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInari Medical does not currently pay a dividend.Dividend GrowthInari Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NARI. Previous Next 1.9 News and Social Media Coverage News SentimentInari Medical has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inari Medical this week, compared to 3 articles on an average week.Search Interest5 people have searched for NARI on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Inari Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inari Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,752,458.00 in company stock.Percentage Held by Insiders13.70% of the stock of Inari Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.19% of the stock of Inari Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inari Medical are expected to grow in the coming year, from ($0.27) to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inari Medical is -113.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inari Medical is -113.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInari Medical has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inari Medical (NASDAQ:NARI) StockInari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Read More Receive NARI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address NARI Stock News HeadlinesJune 7, 2023 | finance.yahoo.comInari Medical Announces Commercial Launch of RevCore™ and Triever16 Curve™, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous ThromboembolismMay 25, 2023 | finance.yahoo.comInari Medical Announces the Release of 2022 Ethos and Sustainability ReportJune 7, 2023 | Chaikin Analytics (Ad)Famous Wall Street Crash System Flashes REDHundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.May 24, 2023 | finance.yahoo.comArtelon, Inc. Secures $20M in Funding to Advance Surgical Treatment of Joint InstabilityMay 22, 2023 | finance.yahoo.comInari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism PatientsMay 21, 2023 | americanbankingnews.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Insider Sells $862,913.12 in StockMay 21, 2023 | americanbankingnews.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 25,000 Shares of StockMay 21, 2023 | americanbankingnews.comInsider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 41,891 Shares of StockJune 7, 2023 | Chaikin Analytics (Ad)Famous Wall Street Crash System Flashes REDHundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.May 21, 2023 | americanbankingnews.comInari Medical (NASDAQ:NARI) Stock Price Down 5% Following Insider SellingMay 18, 2023 | americanbankingnews.comMitch C. Hill Sells 12,750 Shares of Inari Medical, Inc. (NASDAQ:NARI) StockMay 15, 2023 | finance.yahoo.comWall Street Analysts Think Inari Medical, Inc. (NARI) Could Surge 27.7%: Read This Before Placing a BetMay 15, 2023 | finance.yahoo.comCompanies Like Inari Medical (NASDAQ:NARI) Are In A Position To Invest In GrowthMay 15, 2023 | americanbankingnews.comBrokerages Set Inari Medical, Inc. (NASDAQ:NARI) Price Target at $89.11May 12, 2023 | seekingalpha.comInari Medical, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 10, 2023 | msn.comInari Medical: Targeting Underpenetrated $5.8 Billion Thromboembolism MarketMay 10, 2023 | marketwatch.comDeep Vein Thrombosis (DVT) Therapy Market in 2031: Insights, Strategies, and ProjectionsMay 9, 2023 | msn.comLooking Into Inari Medical's Return On Invested CapitalMay 4, 2023 | technews.tmcnet.comSurgical Safety Technologies Furthers its Mission of Improving Operating Room Safety and Efficiency With $15 Million in Series A FundingMay 4, 2023 | msn.comCanaccord Genuity Maintains Inari Medical (NARI) Buy RecommendationMay 4, 2023 | markets.businessinsider.comBTIG Remains a Buy on Inari Medical (NARI)May 3, 2023 | msn.comInari Medical: Q1 Earnings InsightsMay 3, 2023 | finance.yahoo.comInari Medical Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comInari Medical to Present at the Bank of America 2023 Healthcare ConferenceMay 2, 2023 | markets.businessinsider.comWhat Wall Street expects from Inari Medical's earningsMay 2, 2023 | americanbankingnews.comInari Medical (NARI) Scheduled to Post Earnings on WednesdayApril 29, 2023 | americanbankingnews.comShort Interest in Inari Medical, Inc. (NASDAQ:NARI) Decreases By 15.1%See More Headlines NARI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NARI Company Calendar Last Earnings5/03/2023Today6/07/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NARI CUSIPN/A CIK1531048 Webwww.inarimedical.com Phone877-923-4747FaxN/AEmployees1,100Year FoundedN/APrice Target and Rating Average Stock Price Forecast$89.11 High Stock Price Forecast$105.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+46.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,270,000.00 Net Margins-6.87% Pretax Margin-5.87% Return on Equity-6.78% Return on Assets-5.72% Debt Debt-to-Equity RatioN/A Current Ratio8.80 Quick Ratio8.05 Sales & Book Value Annual Sales$383.47 million Price / Sales9.04 Cash FlowN/A Price / Cash FlowN/A Book Value$7.77 per share Price / Book7.81Miscellaneous Outstanding Shares57,170,000Free Float49,339,000Market Cap$3.47 billion OptionableNot Optionable Beta1.12 Key ExecutivesMr. William H. Hoffman (Age 56)CEO, Pres & Director Comp: $1.35MMr. Mitchell C. Hill (Age 64)Chief Financial Officer Comp: $687.42kMr. Andrew J. Hykes (Age 50)Chief Operating Officer Comp: $750.84kDr. Thomas M. Tu M.D. (Age 50)Chief Medical Officer Comp: $752.29kMs. Janet BykVP of Fin. & AccountingMs. Angela AhmadGen. Counsel & Sec.Mr. Eric KhairySr. VP of MarketingMr. John R. Borrell (Age 56)Sr. VP of Sales Ms. Dena TrueloveVP of HRMs. Tara DunnSr. VP of Clinical Affairs & Market Devel.More ExecutivesKey CompetitorsIntegra LifeSciencesNASDAQ:IARTiRhythm TechnologiesNASDAQ:IRTCGlaukosNYSE:GKOSHaemoneticsNYSE:HAEAxonicsNASDAQ:AXNXView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Sold 1,412,759 shares on 6/1/2023Ownership: 0.703%Prelude Capital Management LLCBought 8,023 shares on 6/1/2023Ownership: 0.014%Ontario Teachers Pension Plan BoardSold 2,232 shares on 6/1/2023Ownership: 0.013%ProShare Advisors LLCSold 366 shares on 5/26/2023Ownership: 0.015%Putnam Investments LLCBought 431 shares on 5/22/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions NARI Stock - Frequently Asked Questions Should I buy or sell Inari Medical stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NARI shares. View NARI analyst ratings or view top-rated stocks. What is Inari Medical's stock price forecast for 2023? 8 Wall Street analysts have issued 1 year price targets for Inari Medical's stock. Their NARI share price forecasts range from $70.00 to $105.00. On average, they anticipate the company's share price to reach $89.11 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for NARI or view top-rated stocks among Wall Street analysts. How have NARI shares performed in 2023? Inari Medical's stock was trading at $63.56 on January 1st, 2023. Since then, NARI shares have decreased by 4.6% and is now trading at $60.66. View the best growth stocks for 2023 here. Are investors shorting Inari Medical? Inari Medical saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,370,000 shares, an increase of 25.7% from the April 30th total of 2,680,000 shares. Based on an average daily volume of 838,900 shares, the short-interest ratio is currently 4.0 days. Approximately 7.0% of the shares of the company are sold short. View Inari Medical's Short Interest. When is Inari Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our NARI earnings forecast. How were Inari Medical's earnings last quarter? Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Wednesday, May, 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.19. The company had revenue of $116.17 million for the quarter, compared to analyst estimates of $110.30 million. Inari Medical had a negative trailing twelve-month return on equity of 6.78% and a negative net margin of 6.87%. Inari Medical's revenue was up 33.9% on a year-over-year basis. During the same period last year, the business earned ($0.06) earnings per share. What ETFs hold Inari Medical's stock? ETFs with the largest weight of Inari Medical (NASDAQ:NARI) stock in their portfolio include MFAM Small-Cap Growth ETF (MFMS), Motley Fool Small-Cap Growth ETF (TMFS), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap 400 Pure Growth ETF (RFG), Principal Healthcare Innovators ETF (BTEC), Renaissance IPO ETF (IPO), Goldman Sachs Future Health Care Equity ETF (GDOC) and IQ Healthy Hearts ETF (HART). What guidance has Inari Medical issued on next quarter's earnings? Inari Medical updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $478.00 million-$488.00 million, compared to the consensus revenue estimate of $476.10 million. What other stocks do shareholders of Inari Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY). When did Inari Medical IPO? (NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers. What is Inari Medical's stock symbol? Inari Medical trades on the NASDAQ under the ticker symbol "NARI." Who are Inari Medical's major shareholders? Inari Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.89%), Wellington Management Group LLP (8.87%), Franklin Resources Inc. (4.89%), Price T Rowe Associates Inc. MD (3.26%), State Street Corp (2.90%) and Brown Advisory Inc. (2.29%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Gilde Healthcare Cooperatieve, Kirk G Nielsen, Mitch C Hill, Mitch C Hill, Presidio Management Group X Ll, Stanley Tang, Thomas Tu and William Hoffman. View institutional ownership trends. How do I buy shares of Inari Medical? Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inari Medical's stock price today? One share of NARI stock can currently be purchased for approximately $60.66. How much money does Inari Medical make? Inari Medical (NASDAQ:NARI) has a market capitalization of $3.47 billion and generates $383.47 million in revenue each year. The company earns $-29,270,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. How many employees does Inari Medical have? The company employs 1,100 workers across the globe. How can I contact Inari Medical? Inari Medical's mailing address is 9 Parker Suite 100, Irvine CA, 92618. The official website for the company is www.inarimedical.com. The company can be reached via phone at 877-923-4747 or via email at ir@inarimedical.com. This page (NASDAQ:NARI) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inari Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.